SCHEMBL499230

SCHEMBL499230

CCS(=O)(=O)OS(=O)(=O)CC

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28865074 0.96 CA1 (0.33) CA1CA2
Fluoride SCHEMBL27321968 0.96 CA1 (0.33) CA1CA2
Butane SCHEMBL2384826 0.93 CA1 (0.35) CA1CA2
Butane SCHEMBL2384822 0.93 CA1 (0.35) CA1CA2
SCHEMBL27541078 0.85 CA1 (0.32) CA1CA2
Acetic Acid SCHEMBL21681585 0.84 FFAR3 (0.41)
SCHEMBL18126344 0.84 FAAH (0.35) CA2
SCHEMBL10747079 0.82 CA1 (0.30) CA1CA2
SCHEMBL1043228 0.82 USP2 (0.39) CA1CA2
SCHEMBL11842047 0.82 USP2 (0.32) CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4738518-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME Central Glass Company, Limited (JP) 2026-05-06 EP claimed
EP-4738517-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY Central Glass Company, Limited (JP) 2026-05-06 EP claimed
CN-121586956-A Nonaqueous electrolyte and nonaqueous electrolyte using the same nonaqueous electrolyte battery of aqueous electrolyte 中央硝子株式会社 2026-02-27 CN claimed
US-12227510-B2 Crystal form of acid addition salt of furopyrimidine compound HANMI PHARM. CO., LTD. (KR) 2025-02-18 US claimed
WO-2025028449-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME セントラル硝子株式会社 2025-02-06 WO claimed
WO-2025028448-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY セントラル硝子株式会社 2025-02-06 WO claimed
CN-118993949-A Preparation method of pentafluorophenol ethyl sulfonate used as electrolyte additive 海科新源材料科技(湖北)有限公司 2024-11-22 CN claimed
CN-117936900-A Battery preparation method for inhibiting sodium ion battery gas production, local high-concentration electrolyte and sodium ion battery thereof 广东钠壹新能源科技有限公司 2024-04-26 CN claimed
CN-117304253-A Preparation method and application of diazabicyclo-peptoid derivative 中国药科大学 2023-12-29 CN claimed
WO-2023246631-A1 PREPARATION METHOD FOR DIAZABICYCLO PEPTIDOMIMETIC DERIVATIVE AND USE THEREOF 中国药科大学 2023-12-28 WO claimed
US-20170197914-A1 METHOD FOR PREPARING AN AROMATIC SULFIDE OR SALT THEREOF INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2017-07-13 US claimed
EP-3190139-A1 METHOD FOR PREPARING AN AROMATIC SULFIDE OR SALT THEREOF Industrial Technology Research Institute (TW) 2017-07-12 EP claimed
CN-103694195-A Heterocyclic aromatic micromolecule organic compounds and derivatives, preparation method and medical application UNIV EAST CHINA NORMAL 2014-04-02 CN claimed
US-20120157683-A1 PROCESS FOR THE PREPARATION OF DUTASTERIDE AUROBINDO PHARMA LTD (IN) 2012-06-21 US claimed
US-8106224-B2 Stereospecific method for the preparation of dioxa-bicyclooctane nitrate compounds LACER, S.A. (ES) 2012-01-31 US claimed
WO-2011004242-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF DUTASTERIDE AUROBINDO PHARMA LIMITED (IN) 2011-01-13 WO claimed
US-20100160652-A1 STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS LACER, S.A. (ES) 2010-06-24 US claimed
US-7498431-B2 Process for the preparation of chiral azetidinones FRAMROZE BOMI PATEL 2009-03-03 US claimed
US-20070129540-A1 Process for the preparation of chiral azetidinones OPUS ORGANICS PVT LIMITED (IN) 2007-06-07 US claimed
US-6828448-B2 2-butyl-5-(methanesulfonamido)benzofuran; preparation of dronedarone SANOFI-SYNTHELABO (FR) 2004-12-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197914-A1 METHOD FOR PREPARING AN AROMATIC SULFIDE OR SALT THEREOF C1S, ARSA, TST CA1 1781/4885CA2 611/4885
US-20100160652-A1 STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS TST, NOS3, NOS1 CA1 130/4885CA2 54/4885
US-20070129540-A1 Process for the preparation of chiral azetidinones CYP1B1, ALDH7A1, CYP3A5 CA1 3251/4885CA2 3896/4885
US-20120157683-A1 PROCESS FOR THE PREPARATION OF DUTASTERIDE CYP21A2, CYP17A1, HSD17B7 CA1 525/4885CA2 379/4885
US-12227510-B2 Crystal form of acid addition salt of furopyrimidine compound DPYD, ACR, ATIC CA1 1091/4885CA2 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.